Aortic Stenosis Connect
  • Saved
Predicting the risk of iliofemoral vascular complication in complex transfemoral-TAVR using new generation transcatheter devices

Predicting the risk of iliofemoral vascular complication in complex transfemoral-TAVR using new generation transcatheter devices

Source : https://www.frontiersin.org/articles/10.3389/fcvm.2023.1167212/full

ObjectiveDesign a predictive risk model for minimizing iliofemoral vascular complications (IVC) in a contemporary era of transfemoral-transcatheter aortic valve replacement (TF-TAVR).BackgroundIVC remains a common complication of TF-TAVR despite the technological...

Conclusion: Our CT-based validated-model is the most accurate and easy-to-use tool assessing IVC risk and should be used for calcified and tortuous vessels in preprocedural planning.

 

  • Saved
Evolut PRO/PRO+ versus Evolut R system for transcatheter aortic valve replacement - PubMed

Evolut PRO/PRO+ versus Evolut R system for transcatheter aortic valve replacement - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37479148/

Our largest-to-date observational study suggests that the Evolut PRO/PRO+ system is safe and effective in treating severe aortic stenosis, with commensurate 30-day and 1-year mortality and similar 1-year echocardiographic hemodynamic...

Conclusion: Our largest-to-date observational study suggests that the Evolut PRO/PRO+ system is safe and effective in treating severe aortic stenosis, with commensurate 30-day and 1-year mortality and similar 1-year echocardiographic hemodynamic outcomes in comparison to Evolut R.

  • Saved
Clinical Outcomes of Transcatheter Aortic Valve Replacement with and without Percutaneous Coronary Intervention - An Updated Meta-Analysis and Systematic Review

Clinical Outcomes of Transcatheter Aortic Valve Replacement with and without Percutaneous Coronary Intervention - An Updated Meta-Analysis and Systematic Review

Source : https://www.sciencedirect.com/science/article/abs/pii/S0146280623003973?via=ihub

Transcatheter aortic valve replacement (TAVR) is indicated for high-risk patients with severe degenerative aortic stenosis (AS). Given the shared risk...

Conclusion: Concomitant PCI does not confer any mortality benefit in patients with obstructive CAD and high-grade AS undergoing TAVR. Further trials are needed to confirm our findings.

  • Saved
Impact of TAVR on Patients with Severe Aortic Stenosis and Liver Cirrhosis - PubMed

Impact of TAVR on Patients with Severe Aortic Stenosis and Liver Cirrhosis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37477691/

We sought to assess the impact of transcatheter aortic valve replacement (TAVR) on patients that have both severe aortic stenosis (SAS) and liver cirrhosis on mortality at 365 days after...

Relevance: We sought to assess the impact of transcatheter aortic valve replacement (TAVR) on patients that have both severe aortic stenosis (SAS) and liver cirrhosis on mortality at 365 days after index event. We identified 19,210 patients that met inclusion criteria using the TriNetX database consisting of data from 58 large healthcare...

  • Saved
First-in-Human Multicenter Experience of the Newest Generation Supra-Annular Self-Expanding Evolut FX TAVR System

First-in-Human Multicenter Experience of the Newest Generation Supra-Annular Self-Expanding Evolut FX TAVR System

Source : https://www.sciencedirect.com/science/article/abs/pii/S1936879823008245?via=ihub

The latest-generation Evolut FX TAVR system (Medtronic) offers several potential design improvements over its predecessors, but early reported experie...

Conclusions: The Evolut FX system demonstrated favorable 30-day outcomes with a significant improvement over PRO+ in achieving commissural alignment, fewer device recaptures, and more symmetrical implantation. These features may benefit younger patients undergoing TAVR with the supra-annular, self-expanding valve, where lifetime management...